These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 19145684)

  • 1. Multiple cutaneous ecchymoses associated with the administration of bevacizumab.
    Trafalis DT; Grivas AA; Athanassiou AE
    J BUON; 2008; 13(4):575-6. PubMed ID: 19145684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening.
    Simpkins F; Belinson JL; Rose PG
    Gynecol Oncol; 2007 Oct; 107(1):118-23. PubMed ID: 17658587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implication of bevacizumab in fatal arterial thromboembolic incidents.
    Grivas AA; Trafalis DT; Athanassiou AE
    J BUON; 2009; 14(1):115-7. PubMed ID: 19365880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer.
    Chase JL
    Pharmacotherapy; 2008 Nov; 28(11 Pt 2):23S-30S. PubMed ID: 18980549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer.
    Sandler AB; Johnson DH; Herbst RS
    Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4258s-4262s. PubMed ID: 15217970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antivascular endothelial growth factor monoclonal antibody therapy: a promising paradigm in colorectal cancer.
    Franson PJ; Lapka DV
    Clin J Oncol Nurs; 2005 Feb; 9(1):55-60. PubMed ID: 15751499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cetuximab is effective, but more toxic than reported in the Bonner trial.
    Lord HK; Junor E; Ironside J
    Clin Oncol (R Coll Radiol); 2008 Feb; 20(1):96. PubMed ID: 17928207
    [No Abstract]   [Full Text] [Related]  

  • 8. [Bevacizumab and lung cancer: eligible patients in daily practice].
    Lagnien-Gaume V; Jehl J; Manzoni P; Jacoulet P; Gainet-Brun M; Metzger F; Pernet D; Polio JC; Pugin JF; Corgne J; Amoros C; Dalphin JC; Westeel V
    Rev Mal Respir; 2011 Jan; 28(1):25-31. PubMed ID: 21277471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab for the first-line treatment of human epidermal growth factor receptor 2-negative advanced breast cancer.
    Damasceno M
    Curr Opin Oncol; 2011 Apr; 23 Suppl():S3-9. PubMed ID: 21490481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab.
    Karp JE; Gojo I; Pili R; Gocke CD; Greer J; Guo C; Qian D; Morris L; Tidwell M; Chen H; Zwiebel J
    Clin Cancer Res; 2004 Jun; 10(11):3577-85. PubMed ID: 15173063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab in the treatment of breast cancer.
    Koutras AK; Fountzilas G; Makatsoris T; Peroukides S; Kalofonos HP
    Cancer Treat Rev; 2010 Feb; 36(1):75-82. PubMed ID: 19932567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
    Shih T; Lindley C
    Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer.
    de Gramont A; Van Cutsem E
    Oncology; 2005; 69 Suppl 3():46-56. PubMed ID: 16301835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy.
    Burstein HJ; Chen YH; Parker LM; Savoie J; Younger J; Kuter I; Ryan PD; Garber JE; Chen H; Campos SM; Shulman LN; Harris LN; Gelman R; Winer EP
    Clin Cancer Res; 2008 Dec; 14(23):7871-7. PubMed ID: 19047116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between rash and a positive drug response associated with bevacizumab in a patient with advanced colorectal cancer.
    Saif MW; Longo WL; Israel G
    Clin Colorectal Cancer; 2008 Mar; 7(2):144-8. PubMed ID: 18501075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fournier's gangrene as a possible side effect of bevacizumab therapy for resected colorectal cancer.
    Gamboa EO; Rehmus EH; Haller N
    Clin Colorectal Cancer; 2010 Jan; 9(1):55-8. PubMed ID: 20100690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. "Spontaneous," delayed colon and rectal anastomotic complications associated with bevacizumab therapy.
    August DA; Serrano D; Poplin E
    J Surg Oncol; 2008 Feb; 97(2):180-5. PubMed ID: 18095268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
    Grothey A; Ellis LM
    Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Anti-VEGF therapy with bevacizumab in breast cancer].
    Tóth J; Gonda A; Szántó J
    Lege Artis Med; 2008 Oct; 18(10):669-73. PubMed ID: 19227609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies.
    Hurwitz HI; Saltz LB; Van Cutsem E; Cassidy J; Wiedemann J; Sirzén F; Lyman GH; Rohr UP
    J Clin Oncol; 2011 May; 29(13):1757-64. PubMed ID: 21422411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.